A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Trial details
- Registry ID
- NCT05263999
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Bmab600; EQ001
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)NCT05263999 | Equillium | Phase 3 | Terminated | 2025-04-22Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |